venerdì, 26 novembre 2021
18 Novembre 2019

EU Panel Backs Polatuzumab Vedotin Approval for DLBCL

November 15, 2019 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the antibody-drug conjugate (ADC) polatuzumab vedotin for use in combination with bendamustine and rituximab (BR) for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for a hematopoietic stem cell transplant. The CHMP based its recommendation on … (leggi tutto)